Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for a poster at the American Association for Cancer Research Annual Meeting 2026, April 17–22, 2026.
The poster, "Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast," will be presented April 20, 2026, 2:00–5:00 PM PT in Poster Section 19 and posted online after 5:00 PM PT.
Positive
- None.
Negative
- None.
News Market Reaction – AKTX
On the day this news was published, AKTX declined 24.72%, reflecting a significant negative market reaction. Argus tracked a trough of -18.8% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $10M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows biotech peers PPCB, NRXS, and QTTB moving up, while the scanner flags AKTX’s direction as down. In the broader peer list, most names are modestly down except RNTX, suggesting AKTX’s setup is more stock-specific than part of a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | Strategy/clinical update | Positive | -10.7% | CEO Corner outlining ADC platform progress and path toward clinical development. |
| Feb 26 | Advisory board hire | Positive | -0.7% | Appointment of cancer biology and RNA expert to Scientific Advisory Board. |
| Feb 23 | Advisory board hire | Positive | +2.7% | Addition of globally recognized RNA biology and cancer researcher to advisory board. |
| Feb 18 | Conference presentation | Neutral | -1.6% | Announcement of CEO presentation at Biocom Global Partnering & Investor Conference. |
| Feb 11 | Investor interview | Positive | +1.4% | Virtual investor interview discussing expanded ADC pipeline and AKTX-101 priorities. |
Recent positive strategic and clinical-development updates have often met with flat or negative next-day moves, indicating a tendency for the stock to underreact or sell off on good news.
Over the past months, Akari has focused on building its ADC platform and advancing lead candidate AKTX-101. Management highlighted strategic progress toward IND-enabling work on Mar 13, 2026, and added RNA and cancer biology experts to its Scientific Advisory Board in late February. The company also increased investor outreach via conferences and virtual interviews. Today’s AACR 2026 poster acceptance continues this pattern of scientific visibility and platform-building without yet being a pivotal clinical data event.
Regulatory & Risk Context
The company has an effective S-3 shelf registration dated 2025-07-29, with at least two takedowns via 424B5 filings on 2025-10-16 and 2025-12-17. This structure provides flexibility to raise additional capital as needed, which can be supportive for funding development but may introduce dilution risk when used.
Market Pulse Summary
The stock dropped -24.7% in the session following this news. A negative reaction despite this AACR 2026 poster acceptance would fit a pattern where positive strategic updates sometimes preceded weak next-day performance. With shares already well below the 200-day MA and near the 52-week low, pressure could reflect financing overhang from warrant structures, prior offerings, and an effective S-3 shelf. The announcement itself is a scientific visibility event rather than a decisive clinical data readout.
Key Terms
antibody drug conjugates (ADCs) medical
rna splice modulating payloads medical
trop2 medical
AI-generated analysis. Not financial advice.
TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026.
Details of the poster presentation are as follows:
Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast
Poster Number: 3179
Poster Board Number: 14
Session Category: Experimental and Molecular Therapeutics
Session Title: Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance
Date and Time: Monday, April 20, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 19
The poster presented at the conference will be available for review on the Posters & Publications page on the Company’s website on April 20, 2026 after 5:00 PM PT.
Parties interested in meeting with the Akari team at the conference can direct inquires to info@akaritx.com.
For more information about the American Association for Cancer Research Annual Meeting 2026, please visit aacr.org.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as K-RAS G12V, BRAF G466V, AR-V7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
When and where will Akari Therapeutics (AKTX) present its poster at AACR 2026?
What is the title and focus of Akari Therapeutics' (AKTX) AACR 2026 poster presentation?
How can investors and attendees review Akari Therapeutics' (AKTX) poster after the AACR presentation?
Who should I contact to schedule a meeting with Akari Therapeutics (AKTX) at AACR 2026?
Which session and category includes Akari Therapeutics' (AKTX) poster at AACR 2026?
